Other Events ·
Jaguar Health, Inc. announced on June 22, 2026, that its Board of Directors has initiated a process to explore…
JAGXJaguar Health, Inc.
Jaguar Health, Inc. announced on June 22, 2026, that its Board of Directors has initiated a process to explore strategic alternatives to maximize shareholder value. This exploration is intended to align with the anticipated completion of clinical work for its crofelemer prescription drug candidate for rare intestinal failure diseases in support of a New Drug Application filing. Jaguar Health, Inc. is a healthcare company focused on developing prescription drugs for rare intestinal failure diseases.